Seattle Genetics Reports Third Quarter 2013 Financial Results

06-11-2013 Business Wire HealthComments (0)

Biotechnology

Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the third quarter and nine months ended September 30, 2013. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development activities, progress with its antibody-drug conjugate (ADC) pipeline, collaborator updates and upcoming milestones. “We ended the third quarter in a strong financial position, driven by ADCETRIS net sales and collaboration reven

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top